Amanda B. Kagan

Amanda B. Kagan

Auto-generated profile, based on publicly available information

Amanda B. Kagan

Department of Oncology, School of Medicine Johns Hopkins University Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
AKAmanda B. Kagan
Amanda B. Kagan
DGDominique Garrison
Dominique Garrison
NANicole M. Anders
Nicole M. Anders
JWJonathan A. Webster
Jonathan A. Webster
SBSharyn D. Baker
Sharyn D. Baker
MRMichelle A. Rudek
Michelle A. Rudek
Although DNA methyltransferase inhibitors (DNMTis), such as azacitidine and decitabine, are used extensively in the treatment of myelodysplastic syndromes and acute myeloid leukemia, there remain unanswered questions about DNMTi's mechanism of action and predictors of clinical response. Because patients often remain on single‐agent DNMTis or DNMTi‐containing regimens for several months before knowing whether clinical benefit can be achieved, the development and clinical validation of response‐predictive biomarkers represents an important unmet need in oncology. In this review, we will summarize the clinical studies that led to the approval of azacitidine and decitabine, as well as the real‐world experience with these drugs. We will then focus on biomarker development for DNMTis—specifically, efforts at determining exposure–response relationships and challenges that remain impacting the broader clinical translation of these methods. We will highlight recent progress in liquid‐chromatography tandem mass spectrometry technology that has allowed for the simultaneous measurement of decitabine genomic incorporation and global DNA methylation, which has significant potential as a mechanism‐of‐action based biomarker in patients on DNMTis. Last, we will cover important research questions that need to be addressed in order to optimize this potential biomarker for clinical use.

25 September 2021 in JCO Oncology Practice
Verified
Journal Article
Closed access
LSLaura A. Sena
Laura A. Sena
RSRamy Sedhom
Ramy Sedhom
SSSusan Scott
Susan Scott
AKAmanda Kagan
Amanda Kagan
AMAndrew H. Marple
Andrew H. Marple
AGArjun Gupta
Arjun Gupta
PURPOSE: Oncofertility counseling regarding the reproductive risks associated with cancer therapy is essential for quality cancer care. We aimed to increase the rate of oncofertility counseling for patients of reproductive age (18-40 years) with cancer who were initiating systemic therapy at the Johns Hopkins Cancer Center from a baseline rate of 37% (25 of 68, June 2019-January 2020) to 70% by February 2021. METHODS: We formed an interprofessional, multidisciplinary team as part of the ASCO Quality Training Program. We obtained data from the electronic medical record and verified data with patients by phone. We surveyed patients, oncologists, and fertility specialists to identify barriers. After considering a prioritization matrix, we implemented Plan-Do-Study-Act (PDSA) cycles. RESULTS: We identified the following improvement opportunities: (1) oncologist self-reported lack of knowledge about counseling and local fertility preservation options and (2) lack of a standardized referral mechanism to fertility services. During the first PDSA cycle (February 2020-August 2020, disrupted by COVID-19), we introduced the initiative to increase oncofertility counseling at faculty meetings. From September 2020 to November 2020, we implemented a second PDSA cycle: (1) educating and presenting the initiative at Oncology Grand Rounds, (2) distributing informative pamphlets to oncologists and patients, and (3) implementing an electronic medical record order set. In the third PDSA cycle (December 2020-February 2021), we redesigned the order set to add information (eg, contact information for fertility coordinator) to the patient after-visit summary. Postimplementation (September 2020-February 2021), counseling rates increased from 37% to 81% (38 of 47). CONCLUSION: We demonstrate how a trainee-led, patient-centered initiative improved oncofertility care. Ongoing work focuses on ensuring sustainability and assessing the quality of counseling.

31 August 2022 in Biomedical Chromatography
Verified
Journal Article
Closed access
AKAmanda B. Kagan
Amanda B. Kagan
NANicole M. Anders
Nicole M. Anders
AHAvelina Hemingway
Avelina Hemingway
ELEudocia Q. Lee
Eudocia Q. Lee
KKKevin R. Kelly
Kevin R. Kelly
MRMichelle A. Rudek
Michelle A. Rudek